Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.53 |
| ▸ | CHRNG | P07510 | 1/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | CHRND | Q07001 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272837 | 0.84 | ALDH1A1 (0.49) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL5218170 | 0.80 | CES2 (0.67) | CES2CES1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL7427631 | 0.80 | CES2 (0.67) | CES2CES1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL4273163 | 0.80 | CA12 (0.47) | CES2CES1SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL20090393 | 0.79 | CES2 (0.65) | CES2CES1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2599155 | 0.79 | CES2 (0.65) | CES2CES1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL15007434 | 0.79 | CES2 (0.65) | CES2CES1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL10740779 | 0.78 | SLC6A2 (0.54) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL4272093 | 0.78 | CES2 (0.51) | CES2CES1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL9366959 | 0.78 | CES2 (0.62) | CES2CES1CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910269-B1 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LAB PVT LTD (IN) | 2013-09-18 | — | — | EP | claimed |
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | AVRA LABORATORIES PVT. LTD. (IN) | 2008-09-11 | — | — | US | claimed |
| EP-1910269-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | Avra Laboratories PVT. Ltd. (IN) | 2008-04-16 | — | — | EP | claimed |
| WO-2007015259-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LABORATORIES PVT. LTD. (IN) | 2007-02-08 | — | — | WO | claimed |
| CN-115925608-A | High-efficiency preparation method of high-purity gamma-crystal indometacin | 沈阳化工研究院有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-1910269-B1 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LAB PVT LTD (IN) | 2013-09-18 | — | — | EP | disclosed |
| US-7608740-B2 | Method of synthesizing key intermediates for the production of camptothecin derivatives | Avra Laboratories Pvt. Ltd (IN) | 2009-10-27 | — | — | US | disclosed |
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | AVRA LABORATORIES PVT. LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| EP-1910269-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | Avra Laboratories PVT. Ltd. (IN) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015259-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LABORATORIES PVT. LTD. (IN) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | DHPS, TOP2A, HCCS | CES2 1018/4885CES1 1571/4885CHRNA1 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.